Zhejiang Cheng Yi Pharmaceutical Co Ltd Net Asset Quality Index
Zhejiang Cheng Yi Pharmaceutical Co Ltd net asset quality index. Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) has a Net Asset Quality Index of 81.5% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.75 Billion minus total liabilities of CN¥323.81 Million yields net assets of CN¥1.43 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Zhejiang Cheng Yi Pharmaceutical Co Ltd (2011–2025)
Net asset quality index of Zhejiang Cheng Yi Pharmaceutical Co Ltd from 2011 to 2025. This chart shows how Zhejiang Cheng Yi Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 81.5%, representing net assets of CN¥1.43 Billion against total assets of CN¥1.75 Billion CNY. Check Zhejiang Cheng Yi Pharmaceutical Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Zhejiang Cheng Yi Pharmaceutical Co Ltd Net Asset Quality Index by Year (2011–2025)
Zhejiang Cheng Yi Pharmaceutical Co Ltd net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Zhejiang Cheng Yi Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 82.1% | CN¥1.40 Billion | CN¥1.70 Billion | CN¥304.55 Million | ▲ +8.9 pp |
| 2024 | 73.2% | CN¥1.27 Billion | CN¥1.73 Billion | CN¥463.31 Million | ▲ +10.0 pp |
| 2023 | 63.2% | CN¥1.20 Billion | CN¥1.89 Billion | CN¥696.15 Million | ▼ -0.2 pp |
| 2022 | 63.5% | CN¥1.09 Billion | CN¥1.72 Billion | CN¥628.16 Million | ▼ -12.1 pp |
| 2021 | 75.5% | CN¥998.88 Million | CN¥1.32 Billion | CN¥323.62 Million | ▲ +2.1 pp |
| 2020 | 73.4% | CN¥886.09 Million | CN¥1.21 Billion | CN¥320.79 Million | ▼ -5.0 pp |
| 2019 | 78.4% | CN¥768.96 Million | CN¥980.25 Million | CN¥211.29 Million | ▼ -4.1 pp |
| 2018 | 82.5% | CN¥673.54 Million | CN¥815.99 Million | CN¥142.45 Million | ▼ -6.5 pp |
| 2017 | 89.1% | CN¥599.57 Million | CN¥672.98 Million | CN¥73.41 Million | ▲ +12.2 pp |
| 2016 | 76.9% | CN¥280.17 Million | CN¥364.27 Million | CN¥84.11 Million | ▲ +1.8 pp |
| 2015 | 75.1% | CN¥259.92 Million | CN¥346.13 Million | CN¥86.21 Million | ▲ +0.2 pp |
| 2014 | 74.9% | CN¥246.95 Million | CN¥329.72 Million | CN¥82.77 Million | ▲ +14.6 pp |
| 2013 | 60.3% | CN¥201.40 Million | CN¥333.83 Million | CN¥132.43 Million | ▲ +10.6 pp |
| 2012 | 49.7% | CN¥178.13 Million | CN¥358.12 Million | CN¥179.99 Million | ▲ +15.0 pp |
| 2011 | 34.7% | CN¥102.60 Million | CN¥295.68 Million | CN¥193.09 Million | — |